Clinical Trial Update: Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy) [Phase 2]

View source ↗

Summary

Phase 2 pediatric trial evaluating dupilumab as an adjunct to peanut oral immunotherapy (AR101) for peanut allergy; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peanut Allergy

Drugs mentioned

• AR101 (peanut oral immunotherapy)
• Dupilumab (dupilumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Peanut Allergy | Phase 2 | Status: COMPLETED | Results posted: 2024-02-07